Cargando…
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
The proviral integration of Moloney virus (PIM) family of protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is elevated in PI3K inhibitor-treated breast cancer samples, suggesting a major resistance pathway for PI3K inhibitors in breast cancer, potenti...
Autores principales: | Kennedy, Sean P., O’Neill, Michael, Cunningham, Darren, Morris, Patrick G., Toomey, Sinead, Blanco-Aparicio, Carmen, Martinez, Sonia, Pastor, Joaquin, Eustace, Alex J., Hennessy, Bryan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118022/ https://www.ncbi.nlm.nih.gov/pubmed/32042115 http://dx.doi.org/10.1038/s41388-020-1202-y |
Ejemplares similares
-
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2020) -
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2019) -
Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021) -
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor
por: Ingle, Komala, et al.
Publicado: (2023) -
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)